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Using MY09-MY11 PCR and human papillomavirus (HPV) typing by reverse blot hybridization, we found
a 34% cervical HPV prevalence among 561 pregnant women in Tanzania. One hundred three of 123 women
(84%) with typeable samples harbored high-risk oncogenic strains. HPV type 16 (HPV-16) was the most prev-
alent subtype (18%) among HPV-infected women and among women with cervical neoplasia (3 of 19). A multi-
valent vaccine for HPV-16, -18, -31, -33, and -35 would be necessary to prevent 50% of the neoplasia in this
population.
Cervical cancer is the most common female cancer in sub-
Saharan Africa, with age-standardized incidence rates being
fourfold higher in eastern and southern Africa than in North
America and Europe (9). High-risk oncogenic genital human
papillomaviruses (HR-HPV) have been shown to be the caus-
ative agents of cervical cancer and precancerous or squamous
intraepithelial lesions (SIL) (2, 13). Because cytological or
HPV screening would be logistically difficult and expensive in
most African countries, immunization against HR-HPV offers
the greatest hope for a long-term solution to cervical cancer.
On the basis of epidemiological data showing that HPV type 16
(HPV-16) and HPV-18 are the most frequently detected types
in cervical carcinomas worldwide (1, 2), vaccines currently in
development use HPV-16 and -18 L1 (the major capsid pro-
tein) virus-like particles (VLP) as immunogens (6). Further-
more, the inclusion of HPV-6 and -11 VLP as supplementary
antigens to help prevent genital warts and cervical intraepithe-
lial neoplasia is being pursued (C. J. N. Lacey, personal com-
munication).
Since there is no evidence of cross-protection between HPV
types in natural infection or induced by L1 VLP, the develop-
ment of multivalent vaccines would be desirable (6). We have
conducted a study among a sample of pregnant women attend-
ing a large urban antenatal clinic in northern Tanzania to
determine the prevalence of cervical HPV infections and their
associations with neoplasia and human immunodeficiency virus
(HIV) (7), and we report here a detailed HPV genotype dis-
tribution and its associations with neoplasia and genital warts.
Detailed characteristics of the study population, the samples
taken, and the basic laboratory investigations have been de-
scribed previously (7). We enrolled a systematic sample of con-
senting women attending a busy antenatal clinic in Mwanza,
Tanzania, from April to December 1994. Women were inter-
viewed and underwent genital and pelvic examinations, during
which serum, vaginal, and cervical samples (including a Pap
smear) were collected. Free treatment was provided to all
participants with positive sexually transmitted disease symp-
toms or tests.
Informed written consent was sought, and the patients were
seen by a female clinician in a private room. Patients were
treated on the spot for their sexually transmitted infections
according to the Tanzanian national guidelines. Patients were
counseled on low-risk sexual behavior, offered condoms, and
given a seven-day follow-up appointment for their comprehen-
sive laboratory results, at which time additional treatment was
provided for infections that were not covered by syndromic
treatment at the initial visit. All treatments and investigations
were provided free of charge. Women willing to know their
HIV serostatus were counseled at the clinic, and appropriate
referrals to the then-existing care services were made for HIV-
positive individuals.
This study was approved by the Tanzanian National AIDS
Control Programme and the Tanzanian National Institute for
Medical Research (NIMR) Coordinating Committee. The
study complied with ethical regulations of the World Health
Organization and the London School of Hygiene & Tropical
Medicine.
HPV PCR samples were stored at70°C until shipment and
testing at Imperial College, London, United Kingdom, accord-
ing to a previously described methodology (7). The biotinyl-
ated primers MY09-MY11, HBB01, and GH20-PC04 were
utilized to enable detection of positive PCR products by a
27-genotype reverse blot hybridization assay, as previously de-
scribed (4), with confirmation for HPV-6, -11, -16, -18, and -31
with type-specific PCR primers (12).
Six hundred sixty women with a mean age of 23.4 years
(standard deviation, 5.1; range, 15 to 44) were enrolled. The
majority were married (92%) and had low education levels
(70% with no or only primary schooling). They had a mean
gravidity of 2.7, and few reported more than one sexual partner
in the previous year (10%). Prevalences of HIV (15%), active
syphilis (8%), and cervical infections with Neisseria gonor-
rhoeae or Chlamydia trachomatis (7.5%) were high. External
genital warts were observed in 20 women (3%).
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The prevalence of HPV infection was 34% (190 of 561
patients) among women who had samples adequate for both
HPV PCR analysis and cervical cytology. Of these infected
women, 67 (35%) had genotypes that were not characterized
by the typing system. The relatively frequent detection of such
uncharacterized HPV types by current HPV amplification sys-
tems has been noted by other investigators. For example, in a
study in New Mexico of a population where HIV infection was
infrequent, Peyton et al. (10) found that uncharacterized types
constituted 24% of all genotypes. Genotyping was performed
in our study for the remaining 123 women, from whom 191
distinct HPV isolates from 24 different genotypes were ob-
tained. One hundred two women (54%) harbored high-risk
oncogenic strains, with 46 women (37% of those with known
genotypes) having multiple genotypes (Tables 1 and 2). The
most common genotypes found were HPV-16 (34 women,
18%), HPV-58 (23 women, 12%), HPV-MM7 (19 women,
10%), HPV-33 (20 women, 11%), and HPV-18 (13 women,
7%) (Table 1).
Nineteen HPV-positive women had cervical neoplasia, nine
of whom had high-grade SIL (HSIL). Twelve women had
known genotypes, and all harbored HR-HPV types only. Sev-
enteen infections were detected in these 12 HPV-positive
women with cervical neoplasia, 4 of whom had multiple HPV
types (Table 1). HPV-16 and -33 were the most common types
identified in the subset of women with cervical neoplasia (5 of
19 women, including a woman with dual HPV-16 and -33
infection) and among the women with HSIL (2 of 9 women,
including the dually infected woman) (Table 3). Of the 67
women with unknown HPV genotypes, 3 had low-grade SIL
(LSIL) (all of whom were HIV positive) and 4 had HSIL (none
were HIV positive).
A vaccination strategy targeting only HPV-16 or -18 in this
population would prevent only 4 of 19 cases of cervical neo-
plasia and 2 of 9 cases of HSIL. However, a multivalent vaccine
against HPV-16, -18, -31, -33, and -35 would protect against 9
of 19 cases of cervical neoplasia and 5 of 9 cases of HSIL
(Table 3), and would have prevented infection among 32% of
women (61 of 190 patients). Further work is needed to identify
unknown genotypes and to give form to a vaccination strategy.
Overall, only 19 women (10%) were infected with HPV
types commonly associated with genital warts (HPV-6 and
-11). Six of these women had genital warts (32%), compared
with just 1 of 171 women without these genotypes (P  0.001).
TABLE 1. HPV genotype distribution in all HPV DNA-positive
women and in HPV DNA-positive women with
cervical neoplasia in Mwanza, Tanzania
HPV
genotype
All HPV-positive women
(n  190)
HPV-positive women with
cervical neoplasia (n  19)
No. (%) of
women
% of
isolated types
(no. of typeable
samples, 191)
No. (%) of
women
% of
isolated types
(no. of typeable
samples, 17)
High-risk types
16 34 (18) 18 3 (16) 18
58 23 (12) 12 1 (5) 6
MM7 19 (10) 10 0 0
33 20 (11) 10 3 (19) 18
18 13 (7) 7 1 (5) 6
31 8 (4) 4 2 (11) 12
51 7 (4) 4 2 (11) 12
68 5 (3) 3 0 0
59 4 (2) 2 1 (5) 6
MM4 4 (2) 2 0 0
35 3 (2) 2 2 (11) 12
55 3 (2) 2 1 (5) 6
52 2 (1) 1 1 (5) 6
9 2 (1) 1 0 0
56 2 (1) 1 0 0
26 2 (1) 1 0 0
39 1 (1) 0.5 0 0
45 1 (1) 0.5 0 0
Low-risk types
6 14 (7) 7 0 0
53 12 (6) 6 0 0
11 5 (3) 3 0 0
54 4 (2) 2 0 0
66 2 (1) 1 0 0
MM8 1 (1) 0.5 0 0
Unknown types 67 (35) 7 (37)
TABLE 2. Prevalence of single and multiple HPV infections
Infection type
No./total no. tested (%)
HPV positive HPV positive withcervical neoplasia
Womena Typeablesamples Women
b Typeable
samples
Single infections 77/123 (63) 77/191 (40) 8/12 (67) 8/17 (47)
Multiple infections 46/123 (37) 114/191 (60) 4/12 (33) 9/17 (53)
Multiple infections
with:
2 genotypes 29/46 58/114 3/12 6/9
3 genotypes 12/46 36/114 1/12 3/9
4 genotypes 5/46 20/114 0/12 0/9
a Sixty-seven of 190 women had unknown genotypes and were excluded from
these calculations.
b Seven of 19 women with cervical neoplasia had unknown genotypes and were
excluded from these calculations.
TABLE 3. Distribution of HPV genotypes in 19 HPV
DNA-positive women with cervical neoplasia
in Mwanza, Tanzania
Individual HPV genotype(s) Cervical neoplasia HIV status
1 18 HSIL 
2 33 HSIL 
3 33 LSIL 
4 35 HSIL 
5 35 LSIL 
6 52 LSIL 
7 55 LSIL 
8 59 LSIL 
9 16, 31 LSIL 
10 16, 51 LSIL 
11 31, 51 HSIL 
12 16, 33, 58 HSIL 
13 Unknown LSIL 
14 Unknown LSIL 
15 Unknown LSIL 
16 Unknown HSIL 
17 Unknown HSIL 
18 Unknown HSIL 
19 Unknown HSIL 
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True population-based studies of HPV infection in Africa
have been scarce (3, 11), and few have provided detailed re-
ports on HPV genotypes (3, 5). A recent study conducted in
Mozambique (3) found that HPV-35 was the most prevalent
type among HPV-positive women (16 of 96, 17%) and among
women with cervical neoplasia (7 of 23, 30%) or HSIL (4 of 22,
18%), while HPV-16 and -18 were found only in 13 and 9% of
women with neoplasia and 10 and 0% of women with HSIL or
carcinoma, respectively. It was concluded that the effect of an
HPV-16-based vaccine in preventing cervical neoplasia would
be low, and in this Mozambican population, four genotypes
(HPV-16, -18, -35, and -39) would need to be considered to
prevent at least 70% of neoplasia cases. A study of women with
HSIL from Zimbabwe showed HPV-16, -58, -18, and -52 to be
the most common genotypes, but these women had a high
prevalence of HIV infection (78%) and multiple HPV infec-
tions (68%) (5). We found in our study that cervical neoplasia
was exclusively associated with oncogenic HPVs. However, a
vaccination strategy targeting HPV-16 and HPV-18 would pre-
vent only 21% of cervical neoplasia and HSIL cases. Multiple
types (HPV-16, -18, -31, -33, and -35) would need to be in-
cluded to achieve satisfactory protection from cervical cancer
in this population. Although infrequent, HPV-6 and -11 sub-
types were closely associated with genital warts, and a vaccine
containing these genotypes would prove useful.
The conclusions of these African studies have been limited
by their small sample sizes. Furthermore, their cross-sectional
design does not allow for the capture of the dynamic nature of
HPV infections, with their hallmark features of persistence,
regression, and clearance (8, 14). Finally, the impact of HIV,
both on the persistence of oncogenic HPV types and on the
spectrum of HPV genotypes in invasive cervical cancer in Af-
rica, has not been properly assessed. However, these studies
draw attention to the diversity of HPV types associated with
SIL in Africa and to the fact that currently designed vaccina-
tion strategies may ignore the burden of infection and associ-
ated disease in one of the most affected regions of the world.
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